Navigation Links
Genesis Biopharma Announces Letter to Shareholders Posted to Website
Date:8/30/2011

href="http://www.ncbi.nlm.nih.gov/pubmed/21498393">http://www.ncbi.nlm.nih.gov/pubmed/21498393.  In partnership with key scientists and clinicians at these cancer medical centers, Genesis Biopharma is developing commercial-scale manufacturing, quality and regulatory systems to allow Contego to be delivered to patients as the standard care autologous cell therapy.

We recently partnered with the NCI by entering into a cooperative research and development agreement (CRADA).  The principal investigator is Steven A. Rosenberg, M.D., Ph.D., Chief, Surgery Branch, Center for Cancer Research of the NCI. While the ACT using tumor infiltrating lymphocytes (TIL) therapy approach is proprietary to the NCI, the principal goal of this CRADA is for Genesis and the NCI to collaborate on the development and evaluation of ACT/TIL for the treatment of patients with metastatic melanoma.  

Specifically this CRADA addresses:  (1) the in vitro development of improved methods for the large-scale generation and selection of TIL with anti-tumor reactivity from patients with metastatic melanoma based on ACT therapies developed by and proprietary to the NCI Surgery Branch; (2) the development of these approaches for large-scale TIL production that are in accord with Good Manufacturing Practice suitable for use in treating patients with metastatic melanoma; and, (3) the development of clinical trials using these improved methods of large-scale TIL production as well as improved patient preparative regimens with the goal of commercializing the ACT/TIL therapy approach for treating patients with metastatic melanoma.

Contego is a ready-to-infuse autologous cell therapy using tumor infiltrating lymphocytes that, following approval by the U.S. Food and Drug Administration, will be administered as an in-patient therapy at major cancer medical centers.  

Our strategy of working in partnership with major cancer medical centers offers seve
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao
2. Mummy News: Genesis Medical Imaging Mobile CT Scan Unit Helps Chicagos Field Museum Discover Ancient Secrets
3. Genesis Biopharma to Hold Business Update Conference Call on June 29
4. ThermoGenesis Announces Webcast of Presentation at OnemedForum Conference
5. Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes
6. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
7. CryoLife Announces Completion of Acquisition of Cardiogenesis
8. CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
9. ThermoGenesis Reports Third Quarter Fiscal 2011 Results; Major Progress Achieved in China & India
10. Cardiogenesis Reports First Quarter 2011 Results
11. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... May 6 Vanda Pharmaceuticals Inc. (Nasdaq: ... Drug Administration (FDA) has granted marketing approval of Fanapt(TM) ... schizophrenia. The approval was supported by two placebo-controlled Phase ... control in patients with schizophrenia, as well as safety ...
... provide important insight for physicians in treating heart attack ... BSX ) today welcomed the publication of ... issue of the New England Journal of Medicine. ... Foundation with research grant support from Boston Scientific and ...
Cached Medicine Technology:FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 2FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 3FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 4FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 5FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 6FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 7Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5
(Date:1/22/2015)... Deer Path of Huntley -- a ... Happy Hour from 3 p.m. to 4 p.m. on Feb. 13. ... Huntley, Illinois, serves adults with physical disabilities between the ages of ... Day treats, games and sweetheart-themed karaoke. , For more information about ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... June 15 (HealthDay News) -- Most working fathers say they ... a lot of them admit that they aren,t actually doing ... many dads are conflicted about finding a work-family balance, according ... Family. The survey of nearly 1,000 American fathers with ...
... study by the University of California, San Francisco,s Cardiac Electrophysiology ... causes of sudden cardiac death (SCD), why it is more ... often inaccurately cited as a cause of death. Working ... City and County of San Francisco, researchers will fully investigate ...
... -- Weight loss surgery patients who are discharged from the ... risk of complications and death, a new study has found. ... patients, researchers found that those released from the hospital the ... serious complications (1.9 percent versus 0.16 percent) and 13 times ...
... IOF Regionals 1st Middle-East & Africa Osteoporosis Meeting, ... has published its scientific programme at , http://www.iofbonehealth.org/dubai-2011/programme.html ... is offering awards of 1000 USD each for the ... of age. The abstract deadline is June 17, 2011; ...
... On June 21-23, 2011, the New York Academy ... neuropsychologists, cellular and molecular biologists and patient advocates ... improving diagnosis, treatment and management of the cognitive ... conference titled "Cognitive Dysfunction in Multiple Sclerosis: New ...
... , New York, NY, June 15, 2011A new Commonwealth ... are owned by publicly traded for-profit companies whose primary ... average of 14 percent of premiums on administrative costs, ... by non-publicly traded plans owned by groups of health ...
Cached Medicine News:Health News:Sudden cardiac death subject of sweeping UCSF study in San Francisco 2Health News:Sudden cardiac death subject of sweeping UCSF study in San Francisco 3Health News:Rushed Discharge After Weight-Loss Surgery May Raise Risks 2Health News:Program announced for 1st Middle-East & Africa Osteoporosis Meeting 2Health News:The New York Academy of Sciences to host a symposium on cognitive dysfunction in multiple sclerosis 2Health News:Medicaid managed care plans owned by public companies have higher administrative costs 2Health News:Medicaid managed care plans owned by public companies have higher administrative costs 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: